The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | The future of I-SABR in lung cancer
Joe Chang, MD, PhD, The University of Texas MD Anderson Cancer Centre, Houston, Texas, discusses the future of immunotherapy alongside stereotactic ablative radiotherapy (I-SABR) in the treatment of lung cancer. A current goal is to use radiomic biomarkers to investigate which populations of patients with lung cancer can benefit from I-SABR. Prof. Chang suggests that I-SABR can be used for advanced stage lung cancers in the future and the strategy has been shown to improve progression-free survival in multiple randomised pilot studies. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
